An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

The analysts highlighted the ongoing regulatory review of Arrowhead's leading program, APOC3 targeting siRNA plozasiran, noting its potential benefits from the recent FDA approval of a similar ...